Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
2nd Mitochondria-Targeted Drug Development Summit

2nd Mitochondria-Targeted Drug Development Summit

Categories

Date of beginning

Tuesday, 22 February 2022

Duration

3 days

City

Cambridge

Country

United States

Contact

Mitochondria-Targeted Drug Development Team

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

We are happy to announce that the Mitochondria-Targeted Drug Development Summit, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction, will be delivered in-person, for its 2nd edition. Incorporating insights from leading academics and pioneering biotech, this forum will specifically focus on targeting mitochondrial dysfunction to develop therapies for chronic diseases caused by mitochondrial DNA mutation/nuclear DNA mutations, muscle dystrophy diseases/muscle loss, metabolic disorders, neurodegenerative disease, and conditions linked to oxidative damage. From basic research to the clinic, this year's meeting will examine novel preclinical animal modelling solutions specifically targeting mitochondria, deliver an update on the current leading clinical trials showcasing mitochondrial transfer, mutations, metabolism, quality control, biogenesis, and peroxidation/ oxidation, along with dedicated sessions on the significance on informatics and data sharing for precision medicine. Join 80+ leading experts as they navigate common challenges and opportunities for treating unmet medical needs caused by mitochondrial dysfunction. Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies. URLs:Brochure: https://go.evvnt.com/927944-0?pid=5569 Website:  https://go.evvnt.com/927944-1?pid=5569 Tickets:  https://go.evvnt.com/927944-2?pid=5569  Date and Time: On Tue, Feb 22, 22 ( 9:00 AM) - Thu, Feb 24, 22 ( 5:00 PM) Venue details: Hyatt Regency Boston / Cambridge, 575 Memorial Drive, Cambridge, Massachusetts, 02139, United States Prices:Industry Pricing: Conference + 2 Workshops: USD 4197.00,Industry Pricing: Conference + 1 Workshop: USD 3598.00,Industry Pricing: Conference Only: USD 2999.00,Academic Pricing: Conference + 2 Workshops: USD 3597.00,Academic Pricing: Conference + 1 Workshop: USD 3098.00,Academic Pricing: Conference Only: USD 2599.00,Solution Providers: Conference + 2 Workshops: USD 4997.00,Solution Providers: Conference + 1 Workshop: USD 4298.00,Solution Providers: Conference Only: USD 3599.00 Speakers: Selvaraj Nataraja, Senior Director, Translational Research, Mitobridge/Astellas, Natalie Yivgi-Ohana, Co-Founder and Chief Executive Officer, Minovia, Magali Taiel, Chief Medical Officer, GenSight Biologics, Alexander Schueller, Founder and Chief Executive Officer, Cellvie, Victor Shengkan Jin, Founder, Mito BioPharma, Joseph Sarret, President and Chief Executive Officer, CohBar, Jonah Sinick, Chief Executive Officer, Equator Therapeutics, Rishi Rakhit Director, Translational Medicine, Mitokinin, Gino Cortopassi, Chief Executive Officer, Ixchel Pharma, Matthew Klein, Chief Development Officer, PTC Therapeutics, Ben Albensi, Chief Scientific Officer, Mitrix Bio, Reenie McCarthy, Chief Executive Officer, Stealth Biotherapeutics, Pénélope Andreu, Mitochondrial and Muscle Biology, Amazentis/Vandria, Christopher Missling, President and Chief Executive Officer, Anavex Life Sciences Corp, Bärbel (Barb) Roher, Co-Founder and Chief Scientific Officer, MitoChem Therapeutics, Gregory Flesher, President and Chief Executive Officer, Reneo Pharma, Ellen Donnelly, Chief Executive Officer, Abliva, Michael Fossel, President and Founder, Telocyte, Maxim Skulachev, Chief Scientific Officer, Mitotech, Daria Mochly-Rosen, The George D Professor, Translational Medicine, Professor, Dept Chemical and Systems Biology/Founder and Co-director, Stanford University, School of Medicine/SPARK, Stanford, David Marcinek, Professor of Radiology, Adjunct of Bioengineering and Laboratory Medicine and Pathology, University of Washington Medical School, Hazel Szeto, Co-Founder and Director/Scientific Founder, Improving Global Health, Inc./Stealth BioTherapeutics, Keshav Singh, Joy and Bill Harbert Endowed Chair and Professor/Scientific Founder and Chief Scientific Officer, University of Alabama, Birmingham/Yuva Biosciences, Dan DiPietro, Founding Partner, Aceras Bio, David Schaaf, Vice President, US Medical Affairs, Senior Medical Officer, Zogenix